notebooklm.google.com/notebook/7fc...
AI really takes education to a crazy level, I've uploaded this pdf to NotebookLM website from Google, and it generated this audio track of 2 people discussing the article 🫡
Unleashing power of AI 🤞
I'm interested in being added please
For oncologists based in the UK to share thoughts and discuss cancer treatment paradigm
Inspired by the other great starter packs, UK Oncologists on BlueSky starter pack is up!
Please let me know if you’d like to be added!
go.bsky.app/EfcDXY2
I'm interested in being added,
please
Starting a list of oncology related peopl. Please tell me more to add. Or any similar listd go.bsky.app/GKXp9Fy @n8pennell.bsky.social
The intriguing overall survival results of the PRIMA trial
Will this affect our treatment paradigm? 🤷♂️
Excellent summary of Relevant Clinical Trials With Adjuvant and Neoadjuvant Immunotherapy Components in Resectable NSCLC.
Should we adopt peri-operative approach rather than neoadjuvant pathways? 🫁
"VTE during NACTx chemotherapy for ovarian cancer"
1 in 5 patients undergoing neoadjuvant chemotherapy diagnosed with VTE.
1 in 9 diagnosed after commencing chemotherapy.
leading to delay to treatment and mortality.
Justifies the consideration of thromboprophylaxis.
Do you use Khorana score!!
I'm a lung cancer oncologist based in the UK, interested in being added ✨️
ASCO updated Guideline, Version 2024.2 is now live
Published November 12, 2024
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations.
To me, treating uncommon EGFR mutations (G719X, L861Q, S7681) is still an area of great interest.
Thanks
I'm an oncologist interested in being added ✨️
I'm an oncologist interested in being added ✨️